Skip to main content
ImmuneCited

Beta-Glucan pour Upper Respiratory Tract Infections

A

Meta-analysis of 13 randomized controlled trials shows yeast beta-glucan may help reduce the incidence, number of episodes, and duration of upper respiratory tract infections compared to placebo. A 16-week RCT with 162 participants found 25% reduction in symptomatic cold infections.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dbeta\u002Dglucan\u0026condition\u003Dupper\u002Drespiratory\u002Dinfections'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

En conclusion

Meta-analysis of 13 randomized controlled trials shows yeast beta-glucan may help reduce the incidence, number of episodes, and duration of upper respiratory tract infections compared to placebo. A 16-week RCT with 162 participants found 25% reduction in symptomatic cold infections.

Key Study Findings

Randomized Controlled Trial
The anti-infective effect of β-glucans in children.
Dose: 10 mg vs: Placebo Outcome: Body weight Effet: None None

Population: None

In Vitro
Dry blood spot samples to monitor immune-associated mRNA expression in intervention studies: Impact of Baker's …
Dose: 250 mg/d vs: None Outcome: oxidative stress markers Effet: None None

Population: None

Randomized Controlled Trial 12 weeks Double-blind
β -Glucan Improves Protective Qi Status in Adults with Protective Qi Deficiency-A Randomized, Placebo-Controlled, and …
Dose: None vs: Placebo Outcome: Protective Qi status improvement Effet: None None

Population: Adults with Protective Qi deficiency

Meta-Analysis
Effects of yeast β-glucans for the prevention and treatment of upper respiratory tract infection in …
Dose: 95% vs: placebo Outcome: None Effet: OR = 0.345 p < 0.001

Population: healthy subjects

Randomized Controlled Trial n=69
Soluble and Insoluble Yeast β-Glucan Differentially Affect Upper Respiratory Tract Infection in Marathon Runners: A …
Dose: 250 mL/d vs: Placebo Outcome: None Effet: None None

Population: URTI patients

Randomized Controlled Trial n=132 Double-blind
Beverage Containing Dispersible Yeast β-Glucan Decreases Cold/Flu Symptomatic Days After Intense Exercise: A Randomized Controlled …
Dose: 250 mL/d vs: Placebo Outcome: None Effet: None p < .05

Population: URTI patients

Key Statistics

13

Études

2000

Participants

Positive

A

Note

Referenced Papers

International journal for … 2024 5 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
250-500 mg/day
immunesupport:
250-750 mg/day

Limite supérieure : No established UL

Posologies étudiées dans la recherche

Posologie Durée Effet N
10 mg -- Positive --
250 mg/d -- Positive --
None 12 weeks Positive --
95% -- Positive --
250 mL/d -- Mixed 69
250 mL/d -- Neutral 132
900 mg 16.0 weeks Positive 299
367 mg 12.9 weeks Positive 34

Moment optimal de prise : On empty stomach for optimal immune activation

Safety & Side Effects

Effets indésirables signalés

  • Generally very well tolerated
  • Mild gastrointestinal effects (bloating)
  • Allergic reactions in yeast-sensitive individuals

Interactions connues

  • Immunosuppressant medications (may counteract immunosuppression)
  • Generally few known drug interactions

Apport maximal tolérable : No established UL

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Beta-Glucan help with Upper Respiratory Tract Infections?
Based on 13 studies with 2,000 participants, there is strong evidence from multiple clinical trials that Beta-Glucan may support Upper Respiratory Tract Infections management. Our evidence grade is A (Strong Evidence).
How much Beta-Glucan should I take for Upper Respiratory Tract Infections?
Studies have used various dosages. A commonly studied range is 250-500 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Beta-Glucan?
Reported side effects may include Generally very well tolerated, Mild gastrointestinal effects (bloating), Allergic reactions in yeast-sensitive individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Beta-Glucan and Upper Respiratory Tract Infections?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 13 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.

Related Evidence

Autres ingrédients pour Upper Respiratory Tract Infections

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.